TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04075513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine, 300 U/ml
Description: Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec, 100U/ml
Description: Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy: Rapid acting insulin analogs
Description: Route of administration: SC injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background therapy: Rapid acting insulin analogs
Description: Route of administration: SC injection
Study: NCT04218214

Intervention type: OTHER
Intervention: LIFE-DM Group (Integrated Depression and Livelihood Group Intervention)
Description: Livelihood Integration for Effective Depression Management (LIFE-DM) program aims to address the dual challenges of poverty and depression by integrating evidence-based treatment for depression management and microfinance services. The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and access to microfinance loans. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union. The intervention generally lasts about 3-4 months.
Study: NCT03468751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: recombinant humanized anti-PD-1 monoclonal antibody against solid cancers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: recombinant humanized anti-PD-1 monoclonal antibody against solid cancers
Study: NCT00073736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07133 300mg/m2/day
Description: 7-day continuous infusion in 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07133 600 mg/m2/day
Description: 7-day continuous infusion in 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07133 1200 mg/m2/day
Description: 7-day continuous infusion in 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07133 1800 mg/m2/day
Description: 7-day continuous infusion in 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07133 2400 mg/m2/day
Description: 7-day continuous infusion in 28-day cycles
Study: NCT01142778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab at a dose of 15 mg/kg will be administered as IV infusion over 90 minutes from Cycles 3-6 (1 Cycle=21 days).
Study: NCT00089024

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Restaging with repeat imaging studies will be performed four weeks after completion of the chemo-radiation. If no contraindication for surgical resection is identified, resection will be performed six to eight weeks after completing chemoradiation. At the time of surgical resection, an extensive examination of the abdomen will be performed to exclude the presence of metastatic disease. All operations will be performed with curative intent with resection of all gross tumor (ie R0 \[negative margins\] or R1 \[positive microscopic margins\]). Resection of adjacent involved organs or vascular structures will be performed as clinically indicated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Eligible patients will receive an initial two cycles of chemotherapy with gemcitabine 750 (females) or 900 (males) mg/m5 over 30 minutes followed by a 24-hour infusion of fluorouracil 2700 mg/m5 on days 2 and 9 of a 21-day cycle . Calcium leucovorin 20 mg/m5 will be given orally on days 1 and 8 and by IV push on days 2 and 9 prior to the 5-FU. A window of -2 up to +7 days will be allowed to start planned cycles of therapy provided all other criteria to restart the new cycle has been met. Patients will require a central venous catheter (Port, Hickman or Groshong catheter) for the administration of 5-FU.
Study: NCT01484197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to indacaterol (LB)
Description: Placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to indacaterol (PoS)
Description: Placebo to indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to indacaterol (PoS)
Description: Placebo to indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
Study: NCT03609632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Glucose
Description: Intake of 75g of glucose with 1g of 13C leucine pre-feeding
Study: NCT02254252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorandil
Description: nicorandil (10mg tablets, two times a day)
Study: NCT00910832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eductyl suppository
Description: one suppository every morning during 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suppository
Description: placebo suppository every morning during 21 days
Study: NCT03681366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISC3.5 plus
Description: The Defocus Incorporated Soft 3.5 Plus Contact Lens (DISC3.5 Plus) is a soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
Study: NCT03488719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate 25 MG
Description: A single dose of 25 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate 25 MG
Description: A single dose of 25 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate 25 MG
Description: A single dose of 25 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate 50 MG
Description: A single dose of 50 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate 50 MG
Description: A single dose of 50 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate 50 MG
Description: A single dose of 50 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate 100 MG
Description: A single dose of 100 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21, approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate 100 MG
Description: A single dose of 100 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21, approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate 100 MG
Description: A single dose of 100 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21, approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
Study: NCT03476798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib 600mg PO BID daily
Study: NCT03942640

Intervention type: OTHER
Group type: OTHER
Intervention: subctaneous perineural injection
Description: Buffered glucose preparation :~2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%. Patients received 8 weekly injection

Intervention type: OTHER
Group type: OTHER
Intervention: deep prolotherapy
Description: The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine
Study: NCT04540614

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening exercises programme
Description: Strengthening exercises for Deep Cervical Flexors, Shoulder external rotators, scapular adductors and thoracic erector muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises programme
Description: Strengthening exercises for Deep Cervical Flexors, Shoulder external rotators, scapular adductors and thoracic erector muscles
Study: NCT01814449

Intervention type: OTHER
Intervention: 18FMISO PET/CT scan
Description: The baseline 18F-FMISO PET/CT scans were scheduled before initiation of endocrine therapy. All patients were injected intravenously with 370 MBq of 18F-FMISO and PET/CT static emission scans were conducted at 4 hours after injection.

Intervention type: OTHER
Intervention: 18FMISO PET/CT scan
Description: The baseline 18F-FMISO PET/CT scans were scheduled before initiation of endocrine therapy. All patients were injected intravenously with 370 MBq of 18F-FMISO and PET/CT static emission scans were conducted at 4 hours after injection.

Intervention type: DRUG
Intervention: Letrozole
Description: Patients were assigned to primary endocrine therapy with letrozole 2.5mg daily for at least 4 months.

Intervention type: DRUG
Intervention: Letrozole
Description: Patients were assigned to primary endocrine therapy with letrozole 2.5mg daily for at least 4 months.
Study: NCT00886314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: Children in this group will be premedicated with oral midazolam syrup (0.3 mg.kg) at least 15 minutes before the surgical procedure and one of the parents will be present throughout the anesthesia induction process.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clown doctor
Description: Children will interact with clowns before entering the operating room and will stay with them and one of the parents throughout the anesthesia induction process.
Study: NCT04652102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV
Description: Intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV
Description: Intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program
Description: Intramuscular (IM) injection will be received as standard of care (SoC) outside the study.
Study: NCT02516306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV06 Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Study: NCT00338429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FHP Sleep Program
Description: Cognitive-Behavioral Intervention
Study: NCT03884556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-030
Description: Variable dose and schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-030
Description: Variable dose and schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-030
Description: Variable dose and schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Dose and schedule per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dose and schedule per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: Dose and schedule per standard of care
Study: NCT02950311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal xylitol spray
Description: Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal saline spray
Description: Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
Study: NCT01191138

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Infracolic gastrojejunal anastamosis
Description: Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the infracolic compartment by bringing down the stomach below the mesocolon to the left of the middle colic artery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Supracolic gastrojejunal anastamosis
Description: Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the supracolic compartment.
Study: NCT00528840

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagenase clostridium histolyticum
Description: Up to five injections of AA4500 into cord(s) of the affected hand(s). Each injection was separated by at least 30 days.
Study: NCT03607240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lung ultrasound-guided alveolar recruitment
Description: Alveolar recruitment maneuver will be performed under lung ultrasound-guidance. Positive pressure will be not exceed 40cmH2O and duration of positive pressure inflation will not exceed 10 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional alveolar recruitment
Description: Alveolar recruitment will be provided with positive pressure of 30cmH2O for 10 seconds
Study: NCT02967562

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inflation Breaths

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained Inflation
Study: NCT01466439

Intervention type: PROCEDURE
Group type: OTHER
Intervention: high-frequency of repetitive transcranial magnetic stimulation (rTMS)
Description: frequency of stimulation of 20 Hz

Intervention type: PROCEDURE
Group type: OTHER
Intervention: low frequency of repetitive transcranial magnetic stimulation (rTMS)
Description: frequency of stimulation of 1 Hz
Study: NCT02254252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: sustained-release glyceryl trinitrate (6.4mg tablets, two times a day)
Study: NCT02027896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated medical clearance and surgery
Description: Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
Study: NCT02709733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Motivation Training
Description: Computerized treatment with a virtual reality-based motivation training program, administered for 1 hour per week for 8 weeks.
Study: NCT02875756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 10 revolutions
Description: The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 10 times

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 20 revolutions
Description: The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 20 times
Study: NCT04857905

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microsurgical resection
Description: Depending on the patient's choice, the microsurgical resection of the brain metastases will be performed.
Study: NCT01142778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel at a dose of 100 mg/m\^2 will be administered as IV infusion from Cycles 1-6 (1 Cycle=21 days).
Study: NCT04857905

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gamma Knife radiosurgery
Description: Depending on the patient's choice, the radiosurgical treatment of the brain metastases will be performed.
Study: NCT01142778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel at a dose of 100 mg/m\^2 will be administered as IV infusion from Cycles 1-6 (1 Cycle=21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at a dose of 100 mg/m\^2 will be administered as IV infusion from Cycles 1-6 (1 Cycle=21 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab will be administered as a loading dose of 8 mg/kg as IV infusion in Cycle 1, followed by subsequent dose of 6 mg/kg as IV infusion in Cycles 2 to 7, and during additional 11 cycles post surgery (1 Cycle=21 days).
Study: NCT03198117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: a Chinese traditional medicine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02205112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Study: NCT02866552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stromal Vascular fraction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer lactate
Study: NCT03759847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid intake app
Description: Use of fluid app to monitor intake of fluids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: A survey will be used to assess the usability of the app (ease of use in general, ease of capturing fluid intake data, including the choice of pre-selected volumes for fluid containers, reasons for not using the app more frequently, the usefulness of the app notifications, ease of sending data to the study coordinator for review) as well as to collect recommendations for changes to the app itself.
Study: NCT01965275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib or Gefitinib
Description: Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
Study: NCT02521610

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive the placebo equivalent to RG7625 once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG7625
Description: Participants will receive RG7625 as oral capsules once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
Study: NCT04412824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous blood draw
Description: In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous blood draw
Description: In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session
Study: NCT03053284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide 0.6Mg Solution for Injection
Description: Pasireotide 0.6Mg Solution for Injection will be given once per study visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Saline Solution injection will be given once per study visit
Study: NCT01142778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab will be administered as a loading dose of 8 mg/kg as IV infusion in Cycle 1, followed by subsequent dose of 6 mg/kg as IV infusion in Cycles 2 to 7, and during additional 11 cycles post surgery (1 Cycle=21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as a loading dose of 8 mg/kg as IV infusion in Cycle 1, followed by subsequent dose of 6 mg/kg as IV infusion in Cycles 2 to 7, and during additional 11 cycles post surgery (1 Cycle=21 days).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: All participants will undergo surgery (as per investigator's discretion) after Cycle 7 and between 4 and 6 weeks after the study treatment infusion in Cycle 6 (1 Cycle=21 days).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: All participants will undergo surgery (as per investigator's discretion) after Cycle 7 and between 4 and 6 weeks after the study treatment infusion in Cycle 6 (1 Cycle=21 days).
Study: NCT03720106

Intervention type: OTHER
Group type: OTHER
Intervention: GOAL therapy plan
Description: The GOAL algorithm designs a therapy plan based on the LIMOS assessment, patient goals and subject-specific treatment pathways. The adherence of this therapy plan is examined.
Study: NCT02458742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 0.5%Hyperbaric bupivacaine 2 ml add morphine 50 mcg for spinal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5%Hyperbaric bupivacaine 2 ml for spinal anesthesia
Study: NCT02016586

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maternal Nutritional Supplement
Description: S348S0
Study: NCT00662285

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron supplement: Niferex 100 mg
Description: A: 100 mg pr day in 8 days
Study: NCT03978286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: 10 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: 75 mg per day
Study: NCT06137989

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fill-Up Class ӀӀ restoration
Description: Bulk-fill technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QuiXfil Class ӀӀ restoration
Description: Bulk-fill technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tetric N-Ceram Bulk Fill Class ӀӀ restoration
Description: Bulk-fill technique